Skip to content
Loading…
Summit Therapeutics Inc. shares rose after it said AstraZeneca Plc would make a $2 billion strategic equity investment in the cancer drugmaker to jointly develop drugs.
To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.